Targets › NNRTI
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease.
Open in Phaseline: the race on NNRTI, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Professor Francois Venter | Delstrigo (DOR/3TC/TDF) Non-nucleoside reverse transcriptase inhibitor (doravirine) with nucleoside reverse transc | INSTI, NNRTI | Phase 3 | HIV-1-infection | – |
HIV-1-infection (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.